RadNet (RDNT) To Report Earnings Tomorrow: Here Is What To Expect

RadNet (NASDAQ: RDNT) will report earnings tomorrow after market close. The company previously beat revenue expectations with $575.6 million in revenue, up 22.1% year over year, but missed EPS estimates. For the upcoming quarter, analysts expect revenue growth of 22.1% YoY. The article cites an average analyst price target of $89.75 versus a $71.57 share price.

Original reporting
Published Aug 8, 2026, 3:45 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 8, 2026, 4:13 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
RadNet (RDNT) To Report Earnings Tomorrow: Here Is What To Expect — source image
Decision brief

The 30-second read

$RDNTNeutralMed
01

Why it matters

Traders can use the cited consensus revenue growth and the prior EPS miss as a baseline for positioning into the after-close earnings print, but there is no new disclosure such as updated guidance or a fresh filing.

02

Market read

This is primarily an earnings-timing and expectation setup for RDNT, with some peer read-through and recent price momentum context.

03

What to watch

No details are provided on margins, cash flow, guidance changes, or management commentary, which are typically the key drivers of post-earnings repricing.

Relevance 4/10Novelty 4/10Timing: after market close earnings release tomorrow

Background

The piece is a pre-earnings preview for RadNet, referencing last quarter’s revenue beat and EPS miss, plus consensus expectations for the upcoming quarter.

Company-level read

Ticker impact

$RDNTNeutralMedium confidence
Context

RadNet (RDNT) is scheduled to report earnings next after the close, with the article citing consensus revenue growth and prior quarter results.

Expected impact

Likely volatility around the after-close print, with direction dependent on EPS versus the cited analyst miss and any commentary on revenue growth.

Evidence & confidence

The text provides timing (next after market close) and expectation framing (revenue growth 22.1% YoY, prior quarter EPS miss) but no fresh company disclosure like guidance, revisions, or a new event.

Market effects

Testing and diagnostics services sentiment is described as positive, which can support relative positioning into earnings.

No specific regional impact is disclosed.

No global macro or cross-border catalyst is disclosed.

Counterpoint

The article highlights a prior EPS miss, so upside may be limited if the company’s earnings power remains pressured despite revenue growth.

Key entities

  • RadNet

    Diagnostic imaging company scheduled to report earnings next after market close; article cites prior quarter revenue beat and EPS miss plus consensus revenue growth.

  • Quest Diagnostics

    Peer mentioned as having reported Q2 results with revenue growth and a stock reaction.

  • Guardant Health

    Peer mentioned as having reported Q2 revenues up sharply and a stock reaction.

Related articles

$RDNTMed

DeepHealth Receives Two FDA Clearances Enabling it to Add Cardiovascular Insights and Prior Exam Integration to its AI-Powered Breast Suite

DeepHealth, a RadNet subsidiary (NASDAQ: RDNT), said it received two FDA 510(k) clearances for its Breast Suite: Breast Arterial Calcification (BAC) Assessment and prior-exam integration into ProFound Pro, to be marketed as Mammo Dx. Both are now commercially available in the U.S. DeepHealth reported BAC performance of >90% sensitivity and >88% specificity.

$DLXMed

Deluxe Q2 Earnings Call Highlights

Deluxe (NYSE:DLX) reported Q2 segment results, led by Data Solutions revenue up 21.4% to $82.3M and adjusted EBITDA of $18.1M. Merchant Services revenue rose 6.1% to $107.6M. Print revenue fell 4.3% to $235.9M. Deluxe closed its Celero acquisition on July 31 and raised 2026 guidance: revenue $2.095B-$2.12B, adj. EBITDA $455M-$475M, adj. EPS $3.60-$4.00, and FCF about $200M.

$NEOGMedAI 8/10

Neogen (NEOG) Q4 2026 Earnings Call Transcript

Neogen (NEOG) reported fiscal Q4 2026 revenue of $225.3 million, up 4.3% in core growth, led by Food Safety. Adjusted gross margin rose to 49.7% and adjusted EBITDA grew 12% to $45.4 million. FY2027 guidance: revenue $880-$885 million and adjusted EBITDA $180-$182 million. The company plans a 50% R&D increase and a $140 million genomics divestiture for debt reduction.

$FTSMed

Fortis (FTS) Q2 2026 Earnings Call Transcript

Fortis (FTS) reported Q2 2026 net earnings of C$396 million, up C$26 million year over year, and EPS of C$0.78. Capital expenditures were C$2.7 billion through June, with a C$5.6 billion 2026 plan. Management reiterated 4% to 6% dividend growth through 2030 and cited Tilbury LNG Phase 1B approval and a 9.75% ROE request in an Arizona rate case.

$ANMed

AutoNation (AN) Q2 2026 Earnings Call Transcript

AutoNation (AN) reported Q2 2026 adjusted diluted EPS of $5.56, up 2% year over year, with total revenue of $6.93 billion, essentially flat. After-sales gross profit was a record $607 million, and Customer Financial Services profitability rose to $2,800 per vehicle. ANF net income increased to $11 million and the portfolio grew to $2.67 billion. The company repurchased $457 million of shares and acquired four stores.